Participants diagnosed with CD20-positive B-cell non-Hodgkin lymphoma confirmed by histopathology and/or cell biology who have previously received 2 or more lines of therapy
Eastern Cooperative Oncology Group (ECOG) physical state score: 0-2
Participants must have at least one evaluable or measurable lesion according to Lugano 2014 criteria.
Expected survival of at least 3 months;
Suitable organ and hematopoietic function:
1. The absolute count of neutrophil (ANC) ≥1.0×109/L;
2. Platelets ≥75×10\^9/L (if bone marrow invasion doesn't exist)/≥50.0×10\^9/L (if bone marrow invasion exists);
3. Hemoglobin ≥90 g/L;
4. Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min;
5. Total bilirubin ≤1.5×ULN, alanine aminotransferase ≤2.5×ULN, aspartate aminotransferase ≤2.5×ULN; Subjects with liver lesion: TBIL≤3×ULN, ALT≤5×ULN, AST≤5×ULN;
6. International Standardized ratio and activated partial thromboplastin time ≤1.5 × ULN;
You may not be if
Confirmed central nervous system (CNS) lymphoma.
Subjects who have received allogeneic hematopoietic stem cell transplantation (HSCT) or other organ transplantation
Those who have previously received targeted CD47 or signal regulatory protein α (SIRRP α) therapy.
Previous or current hemolytic anemia, Evans syndrome, arteritis;
Subjects with previous or current other malignant tumors;
Previous or current history of active autoimmune diseases;
Subjects who had undergone major surgery within 4 weeks prior to initial dosing or expected to have major surgery during the study period;
HIV infection, active syphilis, hepatitis B surface antigen (HBsAg) positive and HBV-DNA higher than the lower limit or 1000 copies /ml(500 IU/ml), HCV antibody positive and HCV-RNA higher than the lower limit or 1000 copies /ml
